Ronald Billips
Family Medicine · Bluefield, WVNPI 1881850592
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,583 of the $12,396 with a category attached, or 69.2%. 33 manufacturers reported payments, led by International Rehabilitative Sciences, Inc at 30.7% of the total. 2025 is the largest year on record at $5,214, 4.1 times the $1,260 reported in 2019. Among family medicine clinicians in WV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 537 payments — averaging $23.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- International Rehabilitative Sciences, Inc$4K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- AbbVie$1K
- AstraZeneca$879
- GSK$677
- plus $4K from 27 others
What the payments were for
- Food & beverage$8,58369%
- Education$50%
- Other$3,80831%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| International Rehabilitative Sciences, Inc | 1 | $3,808 |
| Novo Nordisk | 66 | $1,137 |
| Lilly USA, LLC | 76 | $1,021 |
| AbbVie(2 entities) | 56 | $1,020 |
| AstraZeneca | 53 | $879 |
| GSK | 56 | $677 |
| Amgen | 36 | $662 |
| Boehringer Ingelheim | 39 | $636 |
| Merck | 32 | $373 |
| Pfizer | 25 | $283 |
| Bayer | 20 | $279 |
| Novartis | 12 | $210 |
| Mylan Specialty L.p. | 8 | $201 |
| Exact Sciences | 9 | $199 |
| Johnson & Johnson | 10 | $189 |
| Alnylam Pharmaceuticals Inc. | 1 | $109 |
| Xeris Pharmaceuticals, Inc. | 5 | $95 |
| Vifor Pharma, Inc. | 3 | $80 |
| Abbott | 3 | $69 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| Amarin Pharma, Inc. | 3 | $56 |
| Idorsia Pharmaceuticals US Inc | 3 | $53 |
| Dexcom, Inc. | 3 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $38 |
| Hologic Sales And Service, LLC | 2 | $35 |
| Phathom Pharmaceuticals, Inc. | 1 | $33 |
| Gilead | 2 | $29 |
| Verona Pharma, Inc. | 1 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Shield Therapeutics Inc | 1 | $20 |
| Viatris Specialty LLC | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RS-4i Plus with Intersperse$3,808
- RS-SG$3,808
- Repatha$116
- AMVUTTRA$109
How this compares
$12,396 in reported general payments places this provider in the 95th percentile of 843 family medicine providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 85 | $105,768 |
| JanuviaSitagliptin Phosphate | 85 | $104,801 |
| MounjaroTirzepatide | 74 | $96,079 |
| EliquisApixaban | 48 | $61,528 |
| JardianceEmpagliflozin | 29 | $43,511 |
| JanumetSitagliptin Phos/Metformin Hcl | 28 | $37,572 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $36,579 |
| TrulicityDulaglutide | 22 | $33,058 |
| FarxigaDapagliflozin Propanediol | 23 | $28,265 |
| RybelsusSemaglutide | 15 | $25,032 |
| LinzessLinaclotide | 19 | $17,886 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $16,659 |
| Spiriva HandihalerTiotropium Bromide | 12 | $9,780 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $8,280 |
| Novolog FlexpenInsulin Aspart | 22 | $6,998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $373 | $142,373113 claims |
| Novo NordiskOzempic, Rybelsus | $1,137 | $130,800100 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,021 | $129,13796 claims |
| PfizerEliquis | $283 | $61,52848 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $677 | $53,23881 claims |
| Boehringer IngelheimJardiance | $636 | $43,51129 claims |
| AstraZenecaFarxiga, Symbicort | $879 | $34,74345 claims |
| AbbVieLinzess, Synthroid | $1,020 | $20,03837 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 843 family medicine providers in West Virginia.
Other family medicine in Bluefield
- Julie DetempleSouth Charleston$129K
- John CornellHuntington$68K
- Isha WoofterClarksburg$27K
- Dominick WoofterClarksburg$27K
- Ryan RunyonPrinceton$21K
- David HessBridgeport$20K
- Cherry LobatonMartinsburg$19K
- Melissa GamponiaCharleston$18K
- Stephen MascioFollansbee$17K
- Kenneth AdkinsSouth Charleston$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.